Moreover, anthiangiogenic therapies (sunitinib, sorefanib, axitinib, or bevacizumab) have demonstrated an increased response in ccRCC patients with “loss-of-function” mutations (nonsense, frameshift, and in frame), blocking several of the downstream effects of pVHL [49]. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.